Compare
Rinvoq vs. Zeposia

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.

Moderate-to-severe inflammatory conditions in which other treatments haven't worked:

• Rheumatoid arthritis (RA) in adults
• Psoriatic arthritis (PsA) in adults and children ages 2 years and older
• Eczema (atopic dermatitis) in adults and children ages 12 years and older
• Ulcerative colitis (UC) in adults
• Crohn's disease (CD) in adults
• Ankylosing spondylitis (AS) in adults
• Non-radiographic axial spondyloarthritis (nr-axSpA) in adults
• Polyarticular juvenile idiopathic arthritis (pJIA) in adults and children ages 2 years and older

• Upper respiratory tract infection (25%)
• Acne (16%)
• Herpes simplex virus (HSV) infection (8%)
• Headache (6%)

Note: Side effects listed were reported by people who took Rinvoq for eczema.

• Serious infections
• Possible higher risk of death for people with rheumatoid arthritis
• Risk of cancer
• Possible risk of heart attack, stroke, and other blood clots
• Severe allergic reaction
• Stomach and gut tears
• Abnormal lab results (e.g., blood cell counts, cholesterol levels)
• Possible harm to unborn babies
• Medication in stool

Zeposia (ozanimod) treats adults with relapsing forms of multiple sclerosis (MS). This medication can also treat adults with ulcerative colitis (UC). It works as a sphingosine 1-phosphate (S1P) receptor modulator to relieve inflammation in the body. It's a capsule you take by mouth, usually once per day (or as directed by your prescriber if you have liver problems). You use a starter pack for the first week. It helps you slowly raise your dosage to a maintenance level. Side effects include upper respiratory infections and higher liver enzymes. Zeposia (ozanimod) is only available as a brand-name medication.

• Relapsing forms of multiple sclerosis (MS) in adults
• Moderate-to-severe ulcerative colitis (UC) in adults

• Upper respiratory infection (26%)
• High liver enzyme levels (10%)

• Risk of infections
• Risk of brain infection (progressive multifocal leukoencephalopathy)
• Slow heart rate and heart rhythm
• Higher blood pressure
• Liver damage
• Breathing problems
• Eye problem called macular edema
• Brain problem called posterior reversible encephalopathy syndrome (PRES)
• Possible risk of skin cancer
• Harm to an unborn baby